Data

NOTE: A total of 278 participants included in analysis after removing exclusion criteria.

Descriptives

Patient demographics

Overall

Characteristic Non-conventional (n=137) Conventional (n=141) Total (n=278) P-value
Age (y)at the time of result: Mean (SD) 68.81 (14.64) 65.40 (15.10) 67.08 (14.95) 0.06
Age (y)at the time of result: N(%) 0.36
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<65 years 50 (36.5) 60 (42.6) 110 (39.57)
≥65 years 87 (63.5) 81 (57.4) 168 (60.43)
Gender: N(%) 0.58
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Male 82 (59.9) 90 (63.8) 172 (61.87)
Female 55 (40.1) 51 (36.2) 106 (38.13)
Inpatient length of stay: Median (IQ range) 14.00 (8.00-25.00) 12.00 (6.00-24.00) 13.00 (7.00-24.75) 0.18
Height (cm): Mean (SD) 170.45 (10.39) 171.19 (10.34) 170.83 (10.35) 0.55
Weight (kg)within the week prior to dose: Mean (SD) 98.32 (41.03) 88.02 (26.93) 93.10 (34.92) 0.01
BMI: Median (IQ range) 29.45 (24.97-39.68) 28.93 (24.23-33.71) 29.10 (24.43-35.06) 0.13
BMI: N(%) 0.92
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<30 kg/m2 73 (53.3) 77 (54.6) 150 (53.96)
≥30 kg/m2 64 (46.7) 64 (45.4) 128 (46.04)
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: Mean (SD) 48.33 (23.15) 50.35 (27.86) 49.25 (25.36) 0.60
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: N(%) 0.002
Missing 39 (28.5) 58 (41.1) 97 (34.89)
Stage 1: >=90 ml/min 2 (1.5) 0 (0.0) 2 (0.72)
Stage 2: 60-89 ml/min 26 (19.0) 37 (26.2) 63 (22.66)
Stage 3: 30-59 ml/min 49 (35.8) 21 (14.9) 70 (25.18)
Stag3 4/5: <30 ml/min 21 (15.3) 25 (17.7) 46 (16.55)
modified CG (mL/min): Mean (SD) 55.33 (33.27) 65.27 (36.25) 60.37 (35.11) 0.02
CrCl (mL/min): N(%) 0.003
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<50 ml/min 76 (55.5) 52 (36.9) 128 (46.04)
≥50 ml/min 61 (44.5) 89 (63.1) 150 (53.96)
LMWH level: Mean (SD) 0.79 (0.32) 0.88 (0.35) 0.84 (0.34) 0.02
LMWH >1.0: N(%) 0.02
Missing 0 (0.0) 0 (0.0) 0 (0.00)
≤1.0 111 (81.0) 96 (68.1) 207 (74.46)
>1.0 26 (19.0) 45 (31.9) 71 (25.54)
LMWH 0.09
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<0.5 23 (16.8) 13 (9.2) 36 (12.95)
≥0.5 114 (83.2) 128 (90.8) 242 (87.05)
Enoxaparin dose used (mg): Mean (SD) 77.55 (32.75) 88.19 (25.46) 82.95 (29.71) 0.003
Enoxaparin dose (mg/kg): Mean (SD) 0.83 (0.30) 1.01 (0.12) 0.92 (0.24) <0.0001
Concurrent antiplatelet or anticoagulation treatment: N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
No 136 (99.3) 140 (99.3) 276 (99.28)
Yes 1 (0.7) 1 (0.7) 2 (0.72)
Clinical events after anticoagulation (choice=Death): N(%) 0.88
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 127 (92.7) 129 (91.5) 256 (92.09)
Checked 10 (7.3) 12 (8.5) 22 (7.91)
Clinical events after anticoagulation (choice=ACS): N(%) 0.49
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 136 (99.3) 141 (100.0) 277 (99.64)
Checked 1 (0.7) 0 (0.0) 1 (0.36)
Clinical events after anticoagulation (choice=VTE): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 135 (98.5) 139 (98.6) 274 (98.56)
Checked 2 (1.5) 2 (1.4) 4 (1.44)
Clinical events after anticoagulation (choice=Ischaemic stroke in hospital): N(%) 0.24
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 135 (98.5) 141 (100.0) 276 (99.28)
Checked 2 (1.5) 0 (0.0) 2 (0.72)
Major bleeding in hospital: N(%) 0.53
Missing 1 (0.7) 1 (0.7) 2 (0.72)
Yes 8 (5.8) 5 (3.5) 13 (4.68)
No 128 (93.4) 135 (95.7) 263 (94.60)
Indication for enoxaparin(choose as many as apply) (choice=Pulmonary embolism): N(%) 0.24
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 65 (47.4) 56 (39.7) 121 (43.53)
Checked 72 (52.6) 85 (60.3) 157 (56.47)
Indication for enoxaparin(choose as many as apply) (choice=Deep vein thrombosis): N(%) 0.07
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 85 (62.0) 71 (50.4) 156 (56.12)
Checked 52 (38.0) 70 (49.6) 122 (43.88)
Indication for enoxaparin(choose as many as apply) (choice=Atrial fibrillation): N(%) 0.38
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 107 (78.1) 117 (83.0) 224 (80.58)
Checked 30 (21.9) 24 (17.0) 54 (19.42)
Indication for enoxaparin(choose as many as apply) (choice=Myocardial infarction): N(%) 0.62
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 135 (98.5) 140 (99.3) 275 (98.92)
Checked 2 (1.5) 1 (0.7) 3 (1.08)
Indication for enoxaparin(choose as many as apply) (choice=Metallic heart valve): N(%) 0.73
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 130 (94.9) 136 (96.5) 266 (95.68)
Checked 7 (5.1) 5 (3.5) 12 (4.32)
Indication for enoxaparin (Other): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Yes 137 (100.0) 140 (99.3) 277 (99.64)
Other/Unknown 0 (0.0) 1 (0.7) 1 (0.36)
Once daily dosing group: N(%) 0.03
Missing 112 (81.8) 122 (86.5) 234 (84.17)
CrCl>30 once daily enoxaparin dose <1.5mg/kg 16 (11.7) 5 (3.5) 21 (7.55)
CrCl<30 once daily enoxaparin dose <1.0mg/kg 9 (6.6) 14 (9.9) 23 (8.27)

Twice daily dosing

Characteristic Non-conventional (n=108) Conventional (n=112) Total (n=220) P-value
Age (y)at the time of result: Mean (SD) 68.22 (15.21) 64.54 (14.43) 66.35 (14.90) 0.07
Age (y)at the time of result: N(%) 0.25
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<65 years 40 (37.0) 51 (45.5) 91 (41.36)
≥65 years 68 (63.0) 61 (54.5) 129 (58.64)
Gender: N(%) 0.63
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Male 67 (62.0) 74 (66.1) 141 (64.09)
Female 41 (38.0) 38 (33.9) 79 (35.91)
Inpatient length of stay: Median (IQ range) 15.00 (8.00-24.25) 11.00 (6.00-22.00) 13.00 (7.00-22.25) 0.08
Height (cm): Mean (SD) 170.70 (10.50) 172.06 (10.01) 171.39 (10.25) 0.33
Weight (kg)within the week prior to dose: Mean (SD) 100.03 (42.22) 90.30 (28.35) 95.08 (36.09) 0.05
BMI: Median (IQ range) 29.80 (24.99-39.83) 28.96 (24.40-34.01) 29.29 (24.69-36.09) 0.17
BMI: N(%) 0.80
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<30 kg/m2 56 (51.9) 61 (54.5) 117 (53.18)
≥30 kg/m2 52 (48.1) 51 (45.5) 103 (46.82)
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: Mean (SD) 52.04 (22.31) 63.71 (19.92) 57.03 (22.02) 0.002
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: N(%) 0.001
Missing 33 (30.6) 56 (50.0) 89 (40.45)
Stage 1: >=90 ml/min 2 (1.9) 0 (0.0) 2 (0.91)
Stage 2: 60-89 ml/min 23 (21.3) 34 (30.4) 57 (25.91)
Stage 3: 30-59 ml/min 37 (34.3) 20 (17.9) 57 (25.91)
Stag3 4/5: <30 ml/min 13 (12.0) 2 (1.8) 15 (6.82)
modified CG (mL/min): Mean (SD) 59.68 (33.83) 75.26 (31.01) 67.61 (33.28) 0.0005
CrCl (mL/min): N(%) 0.0001
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<50 ml/min 53 (49.1) 26 (23.2) 79 (35.91)
≥50 ml/min 55 (50.9) 86 (76.8) 141 (64.09)
LMWH level: Mean (SD) 0.80 (0.33) 0.90 (0.35) 0.85 (0.34) 0.03
LMWH >1.0: N(%) 0.05
Missing 0 (0.0) 0 (0.0) 0 (0.00)
≤1.0 86 (79.6) 75 (67.0) 161 (73.18)
>1.0 22 (20.4) 37 (33.0) 59 (26.82)
LMWH 0.07
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<0.5 17 (15.7) 8 (7.1) 25 (11.36)
≥0.5 91 (84.3) 104 (92.9) 195 (88.64)
Enoxaparin dose used (mg): Mean (SD) 75.69 (34.48) 89.06 (26.58) 82.50 (31.36) 0.002
Enoxaparin dose (mg/kg): Mean (SD) 0.79 (0.29) 0.99 (0.04) 0.89 (0.23) <0.0001
Concurrent antiplatelet or anticoagulation treatment: N(%) 0.49
Missing 0 (0.0) 0 (0.0) 0 (0.00)
No 107 (99.1) 112 (100.0) 219 (99.55)
Yes 1 (0.9) 0 (0.0) 1 (0.45)
Clinical events after anticoagulation (choice=Death): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 99 (91.7) 102 (91.1) 201 (91.36)
Checked 9 (8.3) 10 (8.9) 19 (8.64)
Clinical events after anticoagulation (choice=ACS): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 108 (100.0) 112 (100.0) 220 (100.00)
Checked 0 (0.0) 0 (0.0) 0 (0.00)
Clinical events after anticoagulation (choice=VTE): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 107 (99.1) 110 (98.2) 217 (98.64)
Checked 1 (0.9) 2 (1.8) 3 (1.36)
Clinical events after anticoagulation (choice=Ischaemic stroke in hospital): N(%) 0.24
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 106 (98.1) 112 (100.0) 218 (99.09)
Checked 2 (1.9) 0 (0.0) 2 (0.91)
Major bleeding in hospital: N(%) 0.37
Missing 1 (0.9) 1 (0.9) 2 (0.91)
Yes 7 (6.5) 4 (3.6) 11 (5.00)
No 100 (92.6) 107 (95.5) 207 (94.09)
Indication for enoxaparin(choose as many as apply) (choice=Pulmonary embolism): N(%) 0.30
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 46 (42.6) 39 (34.8) 85 (38.64)
Checked 62 (57.4) 73 (65.2) 135 (61.36)
Indication for enoxaparin(choose as many as apply) (choice=Deep vein thrombosis): N(%) 0.01
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 71 (65.7) 54 (48.2) 125 (56.82)
Checked 37 (34.3) 58 (51.8) 95 (43.18)
Indication for enoxaparin(choose as many as apply) (choice=Atrial fibrillation): N(%) 0.11
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 86 (79.6) 99 (88.4) 185 (84.09)
Checked 22 (20.4) 13 (11.6) 35 (15.91)
Indication for enoxaparin(choose as many as apply) (choice=Myocardial infarction): N(%) 0.24
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 106 (98.1) 112 (100.0) 218 (99.09)
Checked 2 (1.9) 0 (0.0) 2 (0.91)
Indication for enoxaparin(choose as many as apply) (choice=Metallic heart valve): N(%) 0.33
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 102 (94.4) 109 (97.3) 211 (95.91)
Checked 6 (5.6) 3 (2.7) 9 (4.09)
Indication for enoxaparin (Other): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Yes 108 (100.0) 111 (99.1) 219 (99.55)
Other/Unknown 0 (0.0) 1 (0.9) 1 (0.45)

Once daily dosing

Characteristic Non-conventional (n=29) Conventional (n=29) Total (n=58) P-value
Age (y)at the time of result: Mean (SD) 71.00 (12.28) 68.70 (17.34) 69.85 (14.94) 0.56
Age (y)at the time of result: N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<65 years 10 (34.5) 9 (31.0) 19 (32.76)
≥65 years 19 (65.5) 20 (69.0) 39 (67.24)
Gender: N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Male 15 (51.7) 16 (55.2) 31 (53.45)
Female 14 (48.3) 13 (44.8) 27 (46.55)
Inpatient length of stay: Median (IQ range) 12.00 (8.00-30.00) 18.00 (7.00-28.00) 13.00 (7.25-28.75) 0.86
Height (cm): Mean (SD) 169.53 (10.09) 167.86 (11.06) 168.69 (10.52) 0.55
Weight (kg)within the week prior to dose: Mean (SD) 91.95 (36.22) 79.22 (18.40) 85.59 (29.19) 0.10
BMI: Median (IQ range) 29.04 (23.44-37.35) 28.90 (23.62-31.64) 28.97 (23.49-33.11) 0.53
BMI: N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<30 kg/m2 17 (58.6) 16 (55.2) 33 (56.90)
≥30 kg/m2 12 (41.4) 13 (44.8) 25 (43.10)
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: Mean (SD) 36.22 (22.09) 22.63 (20.61) 28.88 (22.17) 0.03
Estimated Glomerular filtration rate (mL/min)in the 24 h prior to the level: N(%) <0.0001
Missing 6 (20.7) 2 (6.9) 8 (13.79)
Stage 1: >=90 ml/min 0 (0.0) 0 (0.0) 0 (0.00)
Stage 2: 60-89 ml/min 3 (10.3) 3 (10.3) 6 (10.34)
Stage 3: 30-59 ml/min 12 (41.4) 1 (3.4) 13 (22.41)
Stag3 4/5: <30 ml/min 8 (27.6) 23 (79.3) 31 (53.45)
modified CG (mL/min): Mean (SD) 39.14 (25.71) 26.69 (28.62) 32.91 (27.68) 0.09
CrCl (mL/min): N(%) 0.47
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<50 ml/min 23 (79.3) 26 (89.7) 49 (84.48)
≥50 ml/min 6 (20.7) 3 (10.3) 9 (15.52)
LMWH level: Mean (SD) 0.78 (0.31) 0.82 (0.34) 0.80 (0.32) 0.60
LMWH >1.0: N(%) 0.33
Missing 0 (0.0) 0 (0.0) 0 (0.00)
≤1.0 25 (86.2) 21 (72.4) 46 (79.31)
>1.0 4 (13.8) 8 (27.6) 12 (20.69)
LMWH 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
<0.5 6 (20.7) 5 (17.2) 11 (18.97)
≥0.5 23 (79.3) 24 (82.8) 47 (81.03)
Enoxaparin dose used (mg): Mean (SD) 84.48 (24.58) 84.83 (20.64) 84.66 (22.49) 0.95
Enoxaparin dose (mg/kg): Mean (SD) 0.99 (0.31) 1.09 (0.23) 1.04 (0.28) 0.21
Concurrent antiplatelet or anticoagulation treatment: N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
No 29 (100.0) 28 (96.6) 57 (98.28)
Yes 0 (0.0) 1 (3.4) 1 (1.72)
Clinical events after anticoagulation (choice=Death): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 28 (96.6) 27 (93.1) 55 (94.83)
Checked 1 (3.4) 2 (6.9) 3 (5.17)
Clinical events after anticoagulation (choice=ACS): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 28 (96.6) 29 (100.0) 57 (98.28)
Checked 1 (3.4) 0 (0.0) 1 (1.72)
Clinical events after anticoagulation (choice=VTE): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 28 (96.6) 29 (100.0) 57 (98.28)
Checked 1 (3.4) 0 (0.0) 1 (1.72)
Clinical events after anticoagulation (choice=Ischaemic stroke in hospital): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 29 (100.0) 29 (100.0) 58 (100.00)
Checked 0 (0.0) 0 (0.0) 0 (0.00)
Major bleeding in hospital: N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Yes 1 (3.4) 1 (3.4) 2 (3.45)
No 28 (96.6) 28 (96.6) 56 (96.55)
Indication for enoxaparin(choose as many as apply) (choice=Pulmonary embolism): N(%) 0.79
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 19 (65.5) 17 (58.6) 36 (62.07)
Checked 10 (34.5) 12 (41.4) 22 (37.93)
Indication for enoxaparin(choose as many as apply) (choice=Deep vein thrombosis): N(%) 0.60
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 14 (48.3) 17 (58.6) 31 (53.45)
Checked 15 (51.7) 12 (41.4) 27 (46.55)
Indication for enoxaparin(choose as many as apply) (choice=Atrial fibrillation): N(%) 0.58
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 21 (72.4) 18 (62.1) 39 (67.24)
Checked 8 (27.6) 11 (37.9) 19 (32.76)
Indication for enoxaparin(choose as many as apply) (choice=Myocardial infarction): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 29 (100.0) 28 (96.6) 57 (98.28)
Checked 0 (0.0) 1 (3.4) 1 (1.72)
Indication for enoxaparin(choose as many as apply) (choice=Metallic heart valve): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Unchecked 28 (96.6) 27 (93.1) 55 (94.83)
Checked 1 (3.4) 2 (6.9) 3 (5.17)
Indication for enoxaparin (Other): N(%) 1.00
Missing 0 (0.0) 0 (0.0) 0 (0.00)
Yes 29 (100.0) 29 (100.0) 58 (100.00)
Other/Unknown 0 (0.0) 0 (0.0) 0 (0.00)
Once daily dosing group: N(%) 0.03
Missing 4 (13.8) 10 (34.5) 14 (24.14)
CrCl>30 once daily enoxaparin dose <1.5mg/kg 16 (55.2) 5 (17.2) 21 (36.21)
CrCl<30 once daily enoxaparin dose <1.0mg/kg 9 (31.0) 14 (48.3) 23 (39.66)

Subgroups

Anti-Xa >1.0 IU/mL

Characteristic Non-conventional (n=26) Conventional (n=45) Total (n=71) P-value
CrCl (mL/min): N(%) 0.94
<50 ml/min 12 (46.2) 19 (42.2) 31 (43.66)
≥50 ml/min 14 (53.8) 26 (57.8) 40 (56.34)
BMI: N(%) 0.12
<30 kg/m2 15 (57.7) 16 (35.6) 31 (43.66)
≥30 kg/m2 11 (42.3) 29 (64.4) 40 (56.34)
Age (y)at the time of result: N(%) 0.60
<65 years 8 (30.8) 18 (40.0) 26 (36.62)
≥65 years 18 (69.2) 27 (60.0) 45 (63.38)

Anti-Xa <0.5 IU/mL

Characteristic Non-conventional (n=23) Conventional (n=13) Total (n=36) P-value
CrCl (mL/min): N(%) 0.14
<50 ml/min 16 (69.6) 5 (38.5) 21 (58.33)
≥50 ml/min 7 (30.4) 8 (61.5) 15 (41.67)
BMI: N(%) 1.00
<30 kg/m2 15 (65.2) 8 (61.5) 23 (63.89)
≥30 kg/m2 8 (34.8) 5 (38.5) 13 (36.11)
Age (y)at the time of result: N(%) 0.69
<65 years 5 (21.7) 4 (30.8) 9 (25.00)
≥65 years 18 (78.3) 9 (69.2) 27 (75.00)

Anti-Xa (IU/mL): Median (IQR)

Non-conventional Conventional P-value
CrCl (mL/min): <50 ml/min 0.87 (0.66-1.14) 0.71 (0.51-0.90) 0.33
CrCl (mL/min): ≥50 ml/min 0.79 (0.62-1.02) 0.81 (0.60-0.99) 0.05
BMI: <30 kg/m2 0.76 (0.62-0.96) 0.76 (0.54-0.96) 0.005
BMI: ≥30 kg/m2 0.97 (0.73-1.16) 0.77 (0.56-0.94) 0.79
Age (y)at the time of result: <65 years 0.79 (0.64-1.02) 0.79 (0.59-0.94) 0.42
Age (y)at the time of result: ≥65 years 0.83 (0.66-1.09) 0.73 (0.52-0.95) 0.37

Model 1: All patients

Anti-Xa

Model specifications - Outcome: LMWH level
- Covariates: individualised dose, age, modified CrCl, BMI, dosing frequency
- Model: Multiple linear regression
    log(Anti-Xa level) ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq

Global test

model term df1 df2 F.ratio p.value
individualised_dose_used 1 272 7.887 0.005
age 1 272 0.065 0.8
modified_cg 1 272 0.443 0.5
bmi 1 272 4.353 0.04
enoxaparin_freq 1 272 1.487 0.2

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -0.528 (-0.940, -0.116) 0.01
individualised_dose_usedConventional 0.136 (0.041, 0.231) 0.005
age 0.001 (-0.004, 0.005) 0.8
modified_cg -0.001 (-0.003, 0.001) 0.5
bmi 0.005 (0.000, 0.009) 0.04
enoxaparin_freqTwice daily 0.079 (-0.048, 0.207) 0.2

Model diagnostics

Results

Dosing strategy

Contrast Ratio of Geometric means (95% CI) P-value
Conventional / (Non-conventional) 1.146 (1.042, 1.261) 0.005

Adjusted means (95% CI)
individualised_dose_used response SE df lower.CL upper.CL
Non-conventional 0.709 0.028 272 0.656 0.766
Conventional 0.812 0.031 272 0.753 0.876

Modified CrCl

Contrast Ratio of Geometric means (95% CI) P-value
modified_cg61 / modified_cg60 0.999 (0.997, 1.001) 0.5

BMI

Contrast Ratio of Geometric means (95% CI) P-value
bmi30 / bmi29 1.005 (1.000, 1.009) 0.04

Age

Contrast Ratio of Geometric means (95% CI) P-value
age67 / age66 1.001 (0.996, 1.005) 0.8

Dose frequency

Contrast Ratio of Geometric means (95% CI) P-value
Twice daily / Once daily 1.082 (0.952, 1.230) 0.2

Anti-Xa>1.0

Model specifications - Outcome: LMWH level >1.0 (yes/no)
- Covariates: individualised dose, age, modified CrCl, BMI, dosing frequency
- Model: Logistic regression
    Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq

Global test

LR Chisq Df Pr(>Chisq)
individualised_dose_used 9.484 1 0.002
age 0.476 1 0.5
modified_cg 3.641 1 0.06
bmi 3.815 1 0.05
enoxaparin_freq 2.739 1 0.10

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -1.672 (-4.100, 0.755) 0.2
individualised_dose_usedConventional 0.918 (0.318, 1.517) 0.003
age -0.009 (-0.034, 0.016) 0.5
modified_cg -0.011 (-0.023, 0.001) 0.06
bmi 0.025 (0.000, 0.050) 0.05
enoxaparin_freqTwice daily 0.687 (-0.151, 1.524) 0.1

Results

Dosing strategy

Contrast Odds ratios (95% CI) P-value
Conventional / (Non-conventional) 2.50 (1.37, 4.56) 0.003

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 0.99 (0.98, 1.00) 0.06

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 1.03 (1.00, 1.05) 0.05

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 0.99 (0.97, 1.02) 0.5

Dose frequency

Contrast Odds ratios (95% CI) P-value
Twice daily / Once daily 1.99 (0.86, 4.59) 0.1

Anti-Xa<0.5

Model specifications - Outcome: LMWH level <0.5 (yes/no)
- Covariates: individualised dose, age, modified CrCl, BMI, dosing frequency
- Model: Logistic regression
    Anti-Xa level ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq

Global test

LR Chisq Df Pr(>Chisq)
individualised_dose_used 4.859 1 0.03
age 0.058 1 0.8
modified_cg 0.006 1 0.9
bmi 5.938 1 0.01
enoxaparin_freq 1.512 1 0.2

Model summary

Var Coefficients (95% CI) P-value
(Intercept) 0.600 (-2.682, 3.882) 0.7
individualised_dose_usedConventional -0.826 (-1.576, -0.076) 0.03
age -0.004 (-0.036, 0.028) 0.8
modified_cg 0.001 (-0.014, 0.015) 0.9
bmi -0.049 (-0.093, -0.005) 0.03
enoxaparin_freqTwice daily -0.560 (-1.438, 0.319) 0.2

Results

Dosing strategy

Contrast Odds ratios (95% CI) P-value
Conventional / (Non-conventional) 0.44 (0.21, 0.93) 0.03

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 1.00 (0.99, 1.01) 0.9

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 0.95 (0.91, 0.99) 0.03

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 1.00 (0.96, 1.03) 0.8

Dose frequency

Contrast Odds ratios (95% CI) P-value
Twice daily / Once daily 0.57 (0.24, 1.38) 0.2

Model 1b: Twice daily dosing

Anti-Xa>1.0

Model specifications - Outcome: LMWH level >1.0 (yes/no)
- Covariates: individualised dose, age, modified CrCl, BMI
- Model: Logistic regression
    Anti-Xa level ~ individualised dose + age + modified CrCl + BMI

Global test

LR Chisq Df Pr(>Chisq)
individualised_dose_used 9.349 1 0.002
age 0.073 1 0.8
modified_cg 3.815 1 0.05
bmi 5.849 1 0.02

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -1.498 (-4.515, 1.519) 0.3
individualised_dose_usedConventional 1.037 (0.351, 1.724) 0.003
age -0.004 (-0.034, 0.026) 0.8
modified_cg -0.014 (-0.028, 0.000) 0.06
bmi 0.033 (0.006, 0.060) 0.01

Results

Dosing strategy

Contrast Odds ratios (95% CI) P-value
Conventional / (Non-conventional) 2.82 (1.42, 5.61) 0.003

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 0.99 (0.97, 1.00) 0.06

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 1.03 (1.01, 1.06) 0.02

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 1.00 (0.97, 1.03) 0.8

Anti-Xa<0.5

Model specifications - Outcome: LMWH level <0.5 (yes/no)
- Covariates: individualised dose, age, modified CrCl, BMI
- Model: Logistic regression
    Anti-Xa level ~ individualised dose + age + modified CrCl + BMI

Global test

LR Chisq Df Pr(>Chisq)
individualised_dose_used 5.999 1 0.01
age 0.059 1 0.8
modified_cg 0.290 1 0.6
bmi 5.942 1 0.01

Model summary

Var Coefficients (95% CI) P-value
(Intercept) 0.136 (-4.015, 4.286) 0.9
individualised_dose_usedConventional -1.117 (-2.043, -0.191) 0.02
age -0.005 (-0.046, 0.036) 0.8
modified_cg 0.005 (-0.013, 0.022) 0.6
bmi -0.056 (-0.108, -0.005) 0.03

Results

Dosing strategy

Contrast Odds ratios (95% CI) P-value
Conventional / (Non-conventional) 0.33 (0.13, 0.83) 0.02

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 1.00 (0.99, 1.02) 0.6

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 0.95 (0.90, 1.00) 0.03

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 0.99 (0.96, 1.04) 0.8

Model 1c: Once daily dosing

Anti-Xa>2.0

Only univariate test performed due to small sample size.


Model specifications - Outcome: LMWH level >2.0 (yes/no)
- Covariates: individualised dose
- Analysis: Fisher’s exact test
    Anti-Xa level ~ individualised dose

Non-conventional Conventional
LMWH: ≤2.0 0 0
LMWH: >2.0 16 5


P-value (Fisher’s exact test): 1

Anti-Xa<1.0

Only univariate test performed due to small sample size.


Model specifications - Outcome: LMWH level <1.0 (yes/no)
- Covariates: individualised dose
- Analysis: Fisher’s exact test
    Anti-Xa level ~ individualised dose

Non-conventional Conventional
LMWH: <1.0 15 3
LMWH: ≥1.0 1 2


P-value (Fisher’s exact test): 0.1

Anti-Xa>1.0

Only univariate test performed due to small sample size.


Model specifications - Outcome: LMWH level >1.0 (yes/no)
- Covariates: individualised dose
- Analysis: Fisher’s exact test
    Anti-Xa level ~ individualised dose

Non-conventional Conventional
LMWH: ≤1.0 9 11
LMWH: >1.0 0 3


P-value (Fisher’s exact test): 0.3

Anti-Xa<0.5

Only univariate test performed due to small sample size.


Model specifications - Outcome: LMWH level <0.5 (yes/no)
- Covariates: individualised dose
- Analysis: Fisher’s exact test
    Anti-Xa level ~ individualised dose

Non-conventional Conventional
LMWH: <0.5 5 0
LMWH: ≥0.5 11 5


P-value (Fisher’s exact test): 0.3

Model 2: Conventionally dosed patients

Anti-Xa

Model specifications - Outcome: LMWH level
- Covariates: age, modified CrCl, BMI, dosing frequency
- Model: Multiple linear regression
    log(Anti-Xa level) ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq

dat_run2 <- dat_run[dat_run$individualised_dose_used%in%"Conventional",]

Global test

model term df1 df2 F.ratio p.value
age 1 136 0.067 0.8
modified_cg 1 136 4.485 0.04
bmi 1 136 5.469 0.02
enoxaparin_freq 1 136 4.915 0.03

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -0.405 (-0.939, 0.129) 0.1
age -0.001 (-0.006, 0.005) 0.8
modified_cg -0.003 (-0.006, -0.000) 0.04
bmi 0.009 (0.001, 0.017) 0.02
enoxaparin_freqTwice daily 0.221 (0.026, 0.416) 0.03

Model diagnostics

Results

Modified CrCl

Contrast Ratio of Geometric means (95% CI) P-value
modified_cg61 / modified_cg60 0.997 (0.994, 1.000) 0.04

BMI

Contrast Ratio of Geometric means (95% CI) P-value
bmi30 / bmi29 1.009 (1.001, 1.017) 0.02

Age

Contrast Ratio of Geometric means (95% CI) P-value
age67 / age66 0.999 (0.994, 1.005) 0.8

Dose frequency

Contrast Ratio of Geometric means (95% CI) P-value
Twice daily / Once daily 1.247 (1.024, 1.519) 0.03

Anti-Xa>1.0

Model specifications - Outcome: LMWH level >1.0 (yes/no)
- Covariates: age, modified CrCl, BMI, dosing frequency
- Model: Logistic regression
    Anti-Xa level ~ age + modified CrCl + BMI + enoxaparin_freq

Global test

LR Chisq Df Pr(>Chisq)
age 2.981 1 0.08
modified_cg 9.309 1 0.002
bmi 5.865 1 0.02
enoxaparin_freq 4.568 1 0.03

Model summary

Var Coefficients (95% CI) P-value
(Intercept) 0.035 (-3.020, 3.091) 1.0
age -0.029 (-0.061, 0.004) 0.09
modified_cg -0.026 (-0.044, -0.008) 0.004
bmi 0.054 (0.009, 0.100) 0.02
enoxaparin_freqTwice daily 1.312 (0.059, 2.566) 0.04

Results

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 0.97 (0.96, 0.99) 0.004

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 1.06 (1.01, 1.10) 0.02

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 0.97 (0.94, 1.00) 0.09

Dose frequency

Contrast Odds ratios (95% CI) P-value
Twice daily / Once daily 3.72 (1.06, 13.01) 0.04

Anti-xa<0.5

Model specifications - Outcome: lmwh level <0.5 (yes/no)
- Covariates: age, modified crcl, bmi, dosing frequency
- Model: Logistic regression
    Anti-Xa level ~ age + modified crcl + bmi + enoxaparin_freq

Global test

LR Chisq Df Pr(>Chisq)
age 0.176 1 0.7
modified_cg 1.482 1 0.2
bmi 1.396 1 0.2
enoxaparin_freq 3.631 1 0.06

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -1.393 (-6.752, 3.966) 0.6
age 0.011 (-0.042, 0.064) 0.7
modified_cg 0.015 (-0.010, 0.040) 0.2
bmi -0.052 (-0.146, 0.043) 0.3
enoxaparin_freqTwice daily -1.592 (-3.232, 0.049) 0.06

Results

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 1.02 (0.99, 1.04) 0.2

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 0.95 (0.86, 1.04) 0.3

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 1.01 (0.96, 1.07) 0.7

Dose frequency

Contrast Odds ratios (95% CI) P-value
Twice daily / Once daily 0.20 (0.04, 1.05) 0.06

Model 3: Individually dosed patients

Anti-Xa

Model specifications - Outcome: LMWH level
- Covariates: age, modified CrCl, BMI, dosing frequency
- Model: Multiple linear regression
    log(Anti-Xa level) ~ individualised dose + age + modified CrCl + BMI + enoxaparin_freq

Global test

model term df1 df2 F.ratio p.value
age 1 132 0.079 0.8
modified_cg 1 132 0.468 0.5
bmi 1 132 0.885 0.3
enoxaparin_freq 1 132 0.003 1.0

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -0.515 (-1.141, 0.111) 0.1
age 0.001 (-0.005, 0.007) 0.8
modified_cg 0.001 (-0.002, 0.004) 0.5
bmi 0.003 (-0.003, 0.008) 0.3
enoxaparin_freqTwice daily 0.005 (-0.166, 0.176) 1.0

Model diagnostics

Results

Modified CrCl

Contrast Ratio of Geometric means (95% CI) P-value
modified_cg61 / modified_cg60 1.001 (0.998, 1.004) 0.5

BMI

Contrast Ratio of Geometric means (95% CI) P-value
bmi30 / bmi29 1.003 (0.997, 1.008) 0.3

Age

Contrast Ratio of Geometric means (95% CI) P-value
age67 / age66 1.001 (0.994, 1.007) 0.8

Dose frequency

Contrast Ratio of Geometric means (95% CI) P-value
Twice daily / Once daily 1.005 (0.846, 1.194) 1.0

Anti-xa>1.0

Model specifications - Outcome: lmwh level >1.0 (yes/no)
- Covariates: age, modified crcl, bmi, dosing frequency
- Model: Logistic regression
    Anti-Xa level ~ age + modified crcl + bmi + enoxaparin_freq

Global test

LR Chisq Df Pr(>Chisq)
age 0.898 1 0.3
modified_cg 0.279 1 0.6
bmi 0.974 1 0.3
enoxaparin_freq 0.407 1 0.5

Model summary

Var Coefficients (95% CI) P-value
(Intercept) -3.990 (-8.124, 0.144) 0.06
age 0.020 (-0.022, 0.062) 0.3
modified_cg 0.005 (-0.013, 0.022) 0.6
bmi 0.017 (-0.016, 0.049) 0.3
enoxaparin_freqTwice daily 0.380 (-0.817, 1.578) 0.5

Results

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 1.00 (0.99, 1.02) 0.6

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 1.02 (0.98, 1.05) 0.3

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 1.02 (0.98, 1.06) 0.3

Dose frequency

Contrast Odds ratios (95% CI) P-value
Twice daily / Once daily 1.46 (0.44, 4.84) 0.5

Anti-xa<0.5

Model specifications - Outcome: lmwh level <0.5 (yes/no)
- Covariates: age, modified crcl, bmi, dosing frequency
- Model: Logistic regression
    Anti-Xa level ~ age + modified crcl + bmi + enoxaparin_freq

Global test

LR Chisq Df Pr(>Chisq)
age 0.149 1 0.7
modified_cg 0.339 1 0.6
bmi 4.174 1 0.04
enoxaparin_freq 0.098 1 0.8

Model summary

Var Coefficients (95% CI) P-value
(Intercept) 0.900 (-3.482, 5.282) 0.7
age -0.009 (-0.052, 0.035) 0.7
modified_cg -0.006 (-0.025, 0.014) 0.6
bmi -0.047 (-0.097, 0.003) 0.07
enoxaparin_freqTwice daily -0.177 (-1.271, 0.918) 0.8

Results

Modified CrCl

Contrast Odds ratios (95% CI) P-value
modified_cg61 / modified_cg60 0.99 (0.98, 1.01) 0.6

BMI

Contrast Odds ratios (95% CI) P-value
bmi30 / bmi29 0.95 (0.91, 1.00) 0.06

Age

Contrast Odds ratios (95% CI) P-value
age67 / age66 0.99 (0.95, 1.04) 0.7

Dose frequency

Contrast Odds ratios (95% CI) P-value
Twice daily / Once daily 0.84 (0.28, 2.50) 0.8

Session info

Results generated on: 2024-02-19 13:43:38.235789

Click for more details

sessionInfo()
## R version 4.3.2 (2023-10-31)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.3 LTS
## 
## Matrix products: default
## BLAS:   /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0 
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
## 
## locale:
##  [1] LC_CTYPE=en_AU.UTF-8          LC_NUMERIC=C                 
##  [3] LC_TIME=en_AU.UTF-8           LC_COLLATE=en_AU.UTF-8       
##  [5] LC_MONETARY=en_AU.UTF-8       LC_MESSAGES=en_AU.UTF-8      
##  [7] LC_PAPER=en_AU.UTF-8          LC_NAME=en_AU.UTF-8          
##  [9] LC_ADDRESS=en_AU.UTF-8        LC_TELEPHONE=en_AU.UTF-8     
## [11] LC_MEASUREMENT=en_AU.UTF-8    LC_IDENTIFICATION=en_AU.UTF-8
## 
## time zone: Australia/Adelaide
## tzcode source: system (glibc)
## 
## attached base packages:
## [1] splines   grid      stats     graphics  grDevices utils     datasets  methods  
## [9] base     
## 
## other attached packages:
##  [1] progress_1.2.3    Hmisc_5.1-1       REDCapR_1.1.0     xlsx_0.6.5       
##  [5] ggpubr_0.6.0      DiagrammeR_1.0.10 car_3.1-2         carData_3.0-5    
##  [9] fontawesome_0.5.2 MASS_7.3-60.0.1   emmeans_1.10.0    plotly_4.10.4    
## [13] readxl_1.4.3      htmlwidgets_1.6.4 kableExtra_1.4.0  knitr_1.45       
## [17] ggplot2_3.4.4     devtools_2.4.5    usethis_2.2.2     pander_0.6.5     
## [21] magrittr_2.0.3    gridExtra_2.3     rmarkdown_2.25    nvimcom_0.9-145  
## 
## loaded via a namespace (and not attached):
##  [1] remotes_2.4.2.1    sandwich_3.1-0     rlang_1.1.3        multcomp_1.4-25   
##  [5] compiler_4.3.2     systemfonts_1.0.4  vctrs_0.6.5        stringr_1.5.1     
##  [9] profvis_0.3.8      crayon_1.5.2       pkgconfig_2.0.3    fastmap_1.1.1     
## [13] backports_1.4.1    ellipsis_0.3.2     labeling_0.4.3     utf8_1.2.4        
## [17] promises_1.2.1     sessioninfo_1.2.2  purrr_1.0.2        xfun_0.41         
## [21] cachem_1.0.8       jsonlite_1.8.8     highr_0.10         later_1.3.2       
## [25] xlsxjars_0.6.1     prettyunits_1.2.0  broom_1.0.5        cluster_2.1.6     
## [29] R6_2.5.1           bslib_0.6.1        stringi_1.8.3      RColorBrewer_1.1-3
## [33] rpart_4.1.23       pkgload_1.3.4      jquerylib_0.1.4    cellranger_1.1.0  
## [37] estimability_1.4.1 Rcpp_1.0.12        zoo_1.8-12         base64enc_0.1-3   
## [41] nnet_7.3-19        httpuv_1.6.14      Matrix_1.6-5       tidyselect_1.2.0  
## [45] rstudioapi_0.15.0  abind_1.4-5        yaml_2.3.8         codetools_0.2-19  
## [49] miniUI_0.1.1.1     pkgbuild_1.4.3     lattice_0.22-5     tibble_3.2.1      
## [53] shiny_1.8.0        withr_3.0.0        evaluate_0.23      foreign_0.8-86    
## [57] survival_3.5-7     rJava_1.0-11       urlchecker_1.0.1   xml2_1.3.6        
## [61] pillar_1.9.0       checkmate_2.3.1    generics_0.1.3     hms_1.1.3         
## [65] munsell_0.5.0      scales_1.3.0       xtable_1.8-4       glue_1.7.0        
## [69] lazyeval_0.2.2     tools_4.3.2        data.table_1.15.0  ggsignif_0.6.4    
## [73] fs_1.6.3           visNetwork_2.1.2   mvtnorm_1.2-4      tidyr_1.3.1       
## [77] colorspace_2.1-0   htmlTable_2.4.2    Formula_1.2-5      cli_3.6.2         
## [81] fansi_1.0.6        viridisLite_0.4.2  svglite_2.1.3      dplyr_1.1.4       
## [85] gtable_0.3.4       rstatix_0.7.2      sass_0.4.8         digest_0.6.34     
## [89] TH.data_1.1-2      farver_2.1.1       memoise_2.0.1      htmltools_0.5.7   
## [93] lifecycle_1.0.4    httr_1.4.7         mime_0.12